Louisville, KY - February 20, 2008 - Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced the appointment of Robert W. Rounsavall, III to the company’s board of directors.


Founded in February 2007, ACT is focused on the discovery and early development of novel cancer therapeutics as well as the selection for partnership, commercialization and manufacture of the most promising discoveries. Utilizing its groundbreaking business arrangement with the James Graham Brown Cancer Center (Brown Cancer Center) and the University of Louisville Research Foundation, ACT will establish exclusive rights to specific novel therapeutics and fast-track these leading edge discoveries to the pharmaceutical industry, and ultimately the patients who need them.


Mr. Rounsavall is Manager of Dixie Real Properties, LLC, a Louisville based industrial real estate development and management company. He currently serves as a board member for the Regional Cancer Center Corporation, an oversight and advisory board for the Brown Cancer Center; the University of Louisville Board of Overseers; the University of Louisville Foundation and University Medical Center, Inc., which manages University Hospital and the clinical operations of Brown Cancer Center. Mr. Rounsavall previously served on the board of Louisville-based cancer drug development company Aptamera, Inc. from 2003 until the company’s acquisition in 2005 by UK-based Antisoma plc. Aptamera was co-founded by Dr. Don Miller, Director of the University of Louisville’s Brown Cancer Center, to discover, develop and commercialize new anti-cancer drugs.


“We are delighted to have Bob join the ACT board,” said Dale Boden, chairman of the board of directors for ACT. “His twenty years of experience with the Regional Cancer Center Corporation and his active involvement with the Brown Cancer Center and the University of Louisville will be invaluable to ACT as we continue to grow the company.”where he successfully completed several strategic partnerships.  



About Advanced Cancer Therapeutics (ACT):


ACT is a privately held company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Dr. Don Miller, the Brown Cancer Center employs over fifty scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com.



Robert W. Rounsavall, III Joins Advanced Cancer Therapeutics

Board of Directors

Contact:
Randall B. Riggs, President & CEO
Advanced Cancer Therapeutics
Phone: (502) 345-8911
Email:
rriggs@advancedact.com


FOR IMMEDIATE RELEASE